Stock BALPHARMA BAL PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bal Pharma Limited

Equities

BALPHARMA

INE083D01012

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:48 2024-05-16 am EDT 		5-day change 1st Jan Change
100.4 INR +1.34% Intraday chart for Bal Pharma Limited +1.87% -0.07%
Feb. 12 Bal Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
2023 Bal Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 1,094 999.2 461.3 796.7 1,599 1,050
Enterprise Value (EV) 1 2,221 2,231 1,642 1,889 2,607 2,306
P/E ratio 39.3 x 26.4 x -3.78 x 16.1 x 29.1 x 40.8 x
Yield 1.3% 1.42% - 1.86% 0.93% 1.49%
Capitalization / Revenue 0.52 x 0.44 x 0.27 x 0.32 x 0.57 x 0.35 x
EV / Revenue 1.06 x 0.99 x 0.96 x 0.75 x 0.93 x 0.76 x
EV / EBITDA 14.5 x 13.8 x 60.8 x 7.74 x 11.9 x 9.7 x
EV / FCF -20.7 x -30.6 x 12.7 x 29.3 x 25.7 x -9.85 x
FCF Yield -4.82% -3.27% 7.9% 3.41% 3.89% -10.1%
Price to Book 1.68 x 1.5 x 0.88 x 1.49 x 2.73 x 1.65 x
Nbr of stocks (in thousands) 14,172 14,172 14,172 14,822 14,822 15,690
Reference price 2 77.20 70.50 32.55 53.75 107.8 66.93
Announcement Date 8/30/18 8/27/19 9/4/20 9/1/21 8/26/22 8/30/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 2,093 2,250 1,711 2,505 2,812 3,042
EBITDA 1 153.4 161.9 26.99 244.3 219.8 237.8
EBIT 1 104.6 115.7 -28.48 169.2 149.3 174.2
Operating Margin 5% 5.14% -1.66% 6.75% 5.31% 5.73%
Earnings before Tax (EBT) 1 28.83 -2.025 -136.9 41.02 91.82 47.48
Net income 1 27.82 37.88 -122.2 47.42 56.12 25.72
Net margin 1.33% 1.68% -7.14% 1.89% 2% 0.85%
EPS 2 1.963 2.673 -8.621 3.340 3.710 1.639
Free Cash Flow 1 -107.1 -72.86 129.7 64.42 101.4 -234.1
FCF margin -5.12% -3.24% 7.58% 2.57% 3.61% -7.69%
FCF Conversion (EBITDA) - - 480.73% 26.37% 46.14% -
FCF Conversion (Net income) - - - 135.83% 180.73% -
Dividend per Share 2 1.000 1.000 - 1.000 1.000 1.000
Announcement Date 8/30/18 8/27/19 9/4/20 9/1/21 8/26/22 8/30/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 1,127 1,232 1,181 1,093 1,008 1,256
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 7.343 x 7.607 x 43.76 x 4.474 x 4.586 x 5.283 x
Free Cash Flow 1 -107 -72.9 130 64.4 101 -234
ROE (net income / shareholders' equity) 0.63% 3.58% -24.4% 9.55% 10.2% 4.29%
ROA (Net income/ Total Assets) 2.7% 2.77% -0.71% 4.42% 3.73% 3.8%
Assets 1 1,032 1,366 17,151 1,073 1,505 677.4
Book Value Per Share 2 45.90 47.00 37.00 36.10 39.60 40.70
Cash Flow per Share 2 1.910 1.720 0.6100 0.6900 0.7500 0.9500
Capex 1 37.8 85.9 50.6 34.1 84.7 146
Capex / Sales 1.81% 3.82% 2.96% 1.36% 3.01% 4.81%
Announcement Date 8/30/18 8/27/19 9/4/20 9/1/21 8/26/22 8/30/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
BAL PHARMA LIMITED Stock Bal Pharma Limited
-0.07% 18.64M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.20% 709B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.77% 595B
JOHNSON & JOHNSON Stock Johnson & Johnson
-2.29% 367B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.20% 334B
ABBVIE INC. Stock AbbVie Inc.
+4.88% 289B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.32% 239B
NOVARTIS AG Stock Novartis AG
+9.07% 211B
ROCHE HOLDING AG Stock Roche Holding AG
-3.44% 203B
AMGEN INC. Stock Amgen Inc.
+8.47% 171B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BALPHARMA Stock
  4. Financials Bal Pharma Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW